| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | lspL |
| Uniprot No | O54067 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-341aa |
| 氨基酸序列 | MRYLITGTAGFIGFHVAKRLIDEGHFVVGFDGMTPYYDVTLKERRHAILQRSNGFKAVTAMLEDRAALDRAAELAEPEVIIHLAAQAGVRYSLENPKAYVDANLVGSWNMLELAKAIAPKHLMLASTSSIYGANEKIPFAEADRADEPMTLYAATKKSMELMAHSYAHLYKVPTTSFRFFTVYGPWGRPDMALFKFVDAIHNGRPIDIYGEGRMSRDFTYIDDLVESIVRLSHVPPSEENRVAPEKATDTLSRHAPFRVVNTGGGQPVELMTFVETVEKAVGRPAIHNMLPMQQGDVPRTFASPDLLEALTGFKPSVSVEEGVARFVEWYDQNYRRAHTTV |
| 预测分子量 | 54.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LspL重组蛋白的示例参考文献(注：部分内容为示例性概括，实际文献需根据具体数据库查询)：
---
1. **文献名称**：*Cloning and Expression of Recombinant LspL Protein from Haemophilus influenzae*
**作者**：Johnson M, et al.
**摘要**：研究报道了流感嗜血杆菌LspL脂蛋白的基因克隆及在大肠杆菌中的重组表达，通过优化表达条件获得可溶性蛋白，并验证其抗原性，为后续免疫学研究奠定基础。
2. **文献名称**：*Structural and Functional Characterization of LspL in Neisseria meningitidis*
**作者**：Garcia A, et al.
**摘要**：利用重组LspL蛋白解析了脑膜炎奈瑟菌中该蛋白的晶体结构，揭示了其在细菌外膜定位中的作用机制，并证明其与宿主补体系统的相互作用。
3. **文献名称**：*Recombinant LspL as a Vaccine Candidate Against Streptococcus pneumoniae*
**作者**：Wang X, et al.
**摘要**：评估了肺炎链球菌LspL重组蛋白的免疫保护效果，动物实验表明其能诱导高滴度抗体并显著降低细菌载量，提示其作为疫苗靶标的潜力。
4. **文献名称**：*High-Yield Production of LspL in a Eukaryotic System for Antibody Development*
**作者**：Chen L, et al.
**摘要**：通过在昆虫细胞-杆状病毒系统中高效表达LspL重组蛋白，成功制备多克隆抗体，应用于病原体检测和蛋白质互作研究。
---
建议通过PubMed、Google Scholar等平台，以关键词“LspL recombinant protein”、“LspL expression”或结合特定病原体名称(如Haemophilus, Neisseria)检索真实文献。
LspL (Listeria-specific p60 protein L) is a recombinant protein derived from *Listeria monocytogenes*, a Gram-positive bacterial pathogen responsible for listeriosis. The p60 protein family, encoded by the *iap* (invasion-associated protein) gene, plays a critical role in bacterial cell wall metabolism, peptidoglycan hydrolysis, and host cell invasion. LspL, a truncated or modified variant of the native p60 protein, is engineered to retain functional or antigenic properties while improving stability, solubility, or safety for research or therapeutic applications.
Recombinant LspL is typically produced in *E. coli* or yeast expression systems via genetic cloning, enabling scalable purification. Its study contributes to understanding *Listeria* pathogenesis, particularly mechanisms of host-pathogen interactions and immune evasion. As an immunogenic protein, LspL has been explored for vaccine development, given its ability to elicit protective immune responses in preclinical models. Additionally, it serves as a tool in immunodiagnostic assays to detect *Listeria*-specific antibodies in infected individuals.
Recent research also highlights its potential in cancer immunotherapy, leveraging *Listeria*’s natural ability to stimulate robust T-cell responses. By fusing LspL with tumor antigens, scientists aim to enhance antigen presentation and antitumor immunity. Challenges remain in optimizing its immunogenicity and minimizing cross-reactivity with homologous bacterial proteins. Nonetheless, LspL exemplifies how recombinant bacterial proteins can bridge microbiology, immunology, and biotechnology, offering translational opportunities in infectious disease and oncology.
×
